Eli Lilly could extend its lead in its core therapeutic area with the launch of two new products next year. The company also ...

Eli Lilly said its next generation weight-loss drug retatrutide resulted in significant weight loss and reduced knee pain in ...

Eli Lilly is investing $6B in a Huntsville, Ala., plant to make weight-loss and other medicines. Here’s what we know about ...

The site is the third of four new facilities in the U.S. that the pharmaceutical company plans to announce, Eli Lilly said.

French biotech company Abivax's shares rose by over 20% on Wednesday on market rumours that U.S. pharma giant Eli Lilly could ...

Eli Lilly said on Tuesday it will invest more than $6 billion in a new active drug ingredient manufacturing facility in ...

Bank of America sees Eli Lilly's obesity drug growth underestimated, forecasting $3 billion Orfoglipron revenue by 2026 as new therapies expand global market leadership.

Eli Lilly’s weight loss drugs have delivered blockbuster sales in recent quarters. The company is a leader in this market ...

Eli Lilly 's (NYSE: LLY) share price has soared over the past five years (up 530%). In fact, it's hard to find a single ...

Eli Lilly's innovation and pipeline diversification support long-term growth, despite patent risks and competition. Read more ...

Eli Lilly (NYSE: LLY) has outperformed the market over the past 5 years by 31.02% on an annualized basis producing an average annual return of 44.05%. Currently, Eli Lilly has a market capitalization ...

Step aside, semaglutide—retatrutide is showing the most impressive weight loss results of any obesity drug to date.